Buscar en
Medicina Clínica (English Edition)
Toda la web
Inicio Medicina Clínica (English Edition) Antibody responses to influenza vaccine in patients on biological therapy: Resul...
Journal Information
Vol. 153. Issue 10.
Pages 380-386 (November 2019)
Share
Share
Download PDF
More article options
Visits
6
Vol. 153. Issue 10.
Pages 380-386 (November 2019)
Original article
Antibody responses to influenza vaccine in patients on biological therapy: Results of RIER cohort study
Respuesta a la vacuna contra la gripe en pacientes que reciben tratamientos biológicos: resultados del estudio de cohortes RIER
Visits
6
Patricia Richia,
Corresponding author
, María Dolores Martínb, María Teresa Navíoc, Laura González-Hombradod, Marina Salidoe, Jesús Llorentef, Israel Thuissard-Vasallog, Patricia Alcocerh, Carmen María Saa-Requejoi, Ana Jiménez-Diaza, Laura Cebriánc, Leticia Lojoc, Marta García-Castrod, David Sanz-Rosag, Patricia Castroe, Sandra Fernández-Rodríguezj, María José Martínez de Aramayonaj, Martina Steinera, Tatiana Coboa, Cristina García-Fernándezi..., Mónica Fernández-Castroa, Óscar Illeraa, Ricardo Valverdek, Santiago Muñoz-FernándezaVer más
a Rheumatology Department, Infanta Sofía University Hospital, Paseo de Europa 34, San Sebastián de los Reyes, 28702 Madrid, Spain
b Bactereology Department, BR Salud Laboratories, Infanta Sofía University Hospital, Paseo de Europa 34, San Sebastián de los Reyes, 28702 Madrid, Spain
c Rheumatology Department, Infanta Leonor University Hospital, Gran Vía del Este 80, 28031 Madrid, Spain
d Rheumatology Department, Tajo University Hospital, Av. Amazonas Central s/n, Aranjuez, 28300 Madrid, Spain
e Rheumatology Department, Infanta Cristina University Hospital, Av 9 de Junio 2, Parla, 28981 Madrid, Spain
f Pharmacy Department, Infanta Sofía University Hospital, Paseo de Europa 34, San Sebastián de los Reyes, 28702 Madrid, Spain
g School of Doctoral Studies & Research, Europea University, Calle Tajo s/n, Villaviciosa de Odón, 28670 Madrid, Spain
h Rheumatology Department, HM Hospital, Avenida de Manoteras n° 10, 28050 Madrid, Spain
i Preventive Medicine Department, Infanta Sofía University Hospital, Paseo de Europa 34, San Sebastián de los Reyes, 28702 Madrid, Spain
j Occupational Medicine Department, Infanta Sofía University Hospital, Paseo de Europa 34, San Sebastián de los Reyes, 28702 Madrid, Spain
k Dermatology Department, Infanta Sofía University Hospital, Paseo de Europa 34, San Sebastián de los Reyes, 28702 Madrid, Spain
Ver más
This item has received
Article information
Abstract
Full Text
Bibliography
Download PDF
Statistics
Figures (3)
Show moreShow less
Tables (2)
Table 1. Demographic data and disease duration of the 253 patients analyzed.
Table 2. Comparison between basal and final seropositivity against Ag A and Ag B. Data shows n (%).
Show moreShow less
Abstract
Background and objectives

Influenza vaccine is recommended for patients with autoimmune inflammatory rheumatic diseases who receive biological therapy. To evaluate if biological therapy impairs immunization after seasonal influenza vaccine.

Material and methods

Patients with inflammatory arthopathies, psoriasis, inflammatory bowel disease or connective tissue diseases who were receiving or were going to initiate biological therapy were included and vaccinated during 2014–2015 influenza season. ELISA was used to measure influenza antigen A and B antibodies, before and after vaccination. Demographic parameters, diagnosis and kind of treatment were recorded and their influence on the final serological status against influenza was studied.

Results

253 subjects were analyzed. After vaccination, 77% of participants presented detectable antibodies against antigen A and 50.6% of them had detectable antibodies against antigen B. Final seropositivity rate against antigen B antibodies increased from baseline (50.6% vs 43.5%, p<0.001). Anti-TNF drugs were associated with better response and rituximab with the worst (79.2% vs 55.0% for final seropositivity against antigen A, p=0.020). Vaccine response in the rituximab group tended to improve when the interval between the drug administration and the vaccination was at least 12 weeks (seropositivity rate 80.0% in those with the longer interval vs 25.0% in the other group, p=0.054).

Conclusions

Among the patients on biological therapy vaccinated against influenza, anti-TNF therapy was identified as a predictive factor of final seropositivity. Rituximab presented a lower rate of final seropositivity, which could be increased with an accurate administration schedule.

Keywords:
Influenza vaccine
Autoimmune inflammatory diseases
Biological therapy
Anti-TNF
Rituximab
Abreviaturas:
AIIRD
VE
Pso
WHO
Ab
Ag
AU
Abbreviations:
AIIRD
VE
Pso
WHO
Ab
Ag
AU
Resumen
Antecedentes y objetivos

La vacunación antigripal está recomendada en pacientes con enfermedades autoinmunes sistémicas que reciben tratamientos biológicos. Evaluar si la terapia biológica puede perjudicar la inmunización después de la administración de la vacuna contra la gripe estacional.

Material y métodos

Los pacientes con artropatías inflamatorias, psoriasis, enfermedad inflamatoria intestinal o enfermedades del tejido conectivo, que estaban en tratamiento o que iban a iniciar tratamiento con terapia biológica, fueron incluidos en el estudio y vacunados durante la temporada de influenza 2014-2015. Se utilizó ELISA para medir los anticuerpos contra los antígenosA y B de la gripe, antes y después de la vacunación. Se registraron los datos demográficos, diagnósticos y el tipo de tratamiento y se estudió su influencia sobre el estado serológico final contra la influenza.

Resultados

Se analizaron 253 sujetos. Después de la vacunación, el 77% de los participantes presentaron anticuerpos detectables contra el antígeno A y el 50,6% de ellos tenían anticuerpos detectables contra el antígeno B. La tasa de seropositividad final de anticuerpos contra el antígeno B aumentó desde los valores basales (50,6% frente a 43,5%, p<0,001). Los fármacos anti-TNF se asociaron con la mejor respuesta y rituximab con la peor (79,2% vs. 55,0% para la seropositividad final contra el antígeno A, p=0,020). La respuesta a la vacuna en el grupo de rituximab tuvo tendencia a mejorar cuando el intervalo entre la administración del fármaco y la vacunación fue por lo menos de 12 semanas (tasa de seropositividad del 80,0% en aquellos con el intervalo más largo frente al 25% en el otro grupo, p=0.054).

Conclusiones

Entre los pacientes en terapia biológica vacunados contra la influenza, la terapia anti-TNF se identificó como un factor predictivo de la seropositividad final. Rituximab presentó una tasa más baja de seropositividad final, que podría aumentarse con un programa de administración preciso.

Palabras clave:
Vacuna contra la gripe
Enfermedades inflamatorias autoinmunes
Terapia biológica
Anti-TNF
Rituximab

Article

These are the options to access the full texts of the publication Medicina Clínica (English Edition)
Subscriber
Subscriber

If you already have your login data, please click here .

If you have forgotten your password you can you can recover it by clicking here and selecting the option “I have forgotten my password”
Subscribe
Subscribe to

Medicina Clínica (English Edition)

Purchase
Purchase article

Purchasing article the PDF version will be downloaded

Price 19.34 €

Purchase now
Contact
Phone for subscriptions and reporting of errors
From Monday to Friday from 9 a.m. to 6 p.m. (GMT + 1) except for the months of July and August which will be from 9 a.m. to 3 p.m.
Calls from Spain
932 415 960
Calls from outside Spain
+34 932 415 960
E-mail
Article options
Tools
es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos